CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Parabilis Medicines charts $413M IPO to back peptide pipeline

IPO/OfferingPositive
AI Analysis

Summary

Parabilis Medicines, a peptide biotech company led by former Johnson & Johnson R&D head Mathai Mammen, is planning a Nasdaq IPO seeking over $400 million to fund its pipeline.

Importance:6/10
Sentiment:
0.30
IPOPeptideNasdaqBiotechCapital Raise
Related Companies

Read the original article

Published by Endpoints News on June 4, 2026 1:04 PM

Read Original